Know Cancer

or
forgot password
  • cancer clinical trials in durham, NC

  • Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
    Duke Comprehensive Cancer Center
    Durham, North Carolina 27710
    Breast Cancer, Carcinoma of the Breast
    Efficacy Study of ABR-215050 to Treat Prostate Cancer
    Duke University Medical Center
    Durham, North Carolina 27710
    Prostate Cancer
    CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
    Duke University Medical Center
    Durham, North Carolina 27710
    Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme
    Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
    Duke University Medical Center
    Durham, North Carolina 27710
    Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
    Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
    Duke University
    Durham, North Carolina 27710
    Breast Cancer, Bone Metastases
    Statin Therapy Versus Placebo Prior to Prostatectomy
    Durham VA Medical Center, Durham, NC
    Durham, North Carolina 27705
    Cancer, Prostate
    Learning Impairments Among Survivors of Childhood Cancer
    Duke University Medical Center
    Durham, North Carolina 27710
    Acute Lymphoblastic Leukemia, Brain Tumors
    Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
    Duke University Comprehensive Cancer Center
    Durham, North Carolina 27710
    Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
    Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
    Duke University Medical Center
    Durham, North Carolina 27710
    Lymphoma, B-Cell
    Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath
    Duke University Health Systems
    Durham, North Carolina 27710
    Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors
    Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
    Duke University Health Systems
    Durham, North Carolina 27710
    Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors
    A Research Pilot Study in Healthy Volunteers to Evaluate Biomarkers for Novel Anticancer Treatments
    Duke University Medical Center
    Durham, North Carolina 27710
    Healthy
    BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)
    Duke University Medical Center
    Durham, North Carolina 27710
    Solid Tumors
    Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT
    Duke University Health System
    Durham, North Carolina 27705
    Lymphoma
    Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT
    Duke University Health Systems
    Durham, North Carolina 27710
    Lymphoma
    Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
    Duke University Health System
    Durham, North Carolina 27705
    Glioblastoma, Gliosarcoma, Brain Tumor
    Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant
    Duke University Health System
    Durham, North Carolina 27705
    Hodgkin's Disease, Non Hodgkin's Lymphoma, Myeloma, Leukemia, Myelodysplasia
    Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
    Duke University Health System
    Durham, North Carolina 27705
    Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors, Hodgkin's Disease, Myelofibrosis
    Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas
    Duke University Health System
    Durham, North Carolina 27705
    Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
    Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma
    Duke University Health System
    Durham, North Carolina 27705
    Glioblastoma, Gliosarcoma
    Ph II Bevacizumab + Etoposide for Pts w Recurrent MG
    Duke University Health System
    Durham, North Carolina 27705
    Glioblastoma, Gliosarcoma
    Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
    Duke University Medical Center
    Durham, North Carolina 27710
    Hepatic Veno-Occlusive Disease
    Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
    Duke University Medical Center
    Durham, North Carolina 27710
    Malignant Neoplasms of Brain
    Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
    Duke University Medical Center
    Durham, North Carolina 27710
    Malignant Neoplasms of Brain
    Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism
    Duke University Medical Center
    Durham, North Carolina 27710
    Venous Thrombosis
    Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
    Duke Comprehensive Cancer Center
    Durham, North Carolina 27710
    Leukemia
    A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation
    Duke Comprehensive Cancer Center
    Durham, North Carolina 27710
    Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), B Cell Malignancies
    Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
    Duke University Medical Center
    Durham, North Carolina 27710
    Metastatic Melanoma, Absence of CNS Metastases
    Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy
    Duke University Medical Center
    Durham, North Carolina 27710
    Prostate Cancer, Prostatectomy
    Evaluation of the Duration of Therapy for Thrombosis in Children
    Duke University
    Durham, North Carolina 27710
    Venous Thrombosis
    Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance RX
    Duke University Medical Center
    Durham, North Carolina 27710
    Multiple Myeloma
    Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer
    Duke University Medical Center
    Durham, North Carolina 27710
    Glioblastoma
    Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy
    Duke University Medical Center

    Trial Locations
    Duke University Medical Center
    Durham Veterans Affairs Medical Center
    Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
    Duke University Medical Center
    Durham, North Carolina 27710
    Non Small Cell Lung Cancer
    Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)
    Duke University Medical Center
    Durham, North Carolina 27710
    Adenovirus Infection, EBV Infection
    Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study
    Duke University Medical Center
    Durham, North Carolina 27710
    Secondary Acute Myeloid Leukemia (Secondary AML, sAML)
    Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
    Duke Cancer Institute
    Durham, North Carolina 27710
    Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ototoxicity, Ovarian Cancer, Sarcoma
    A Study Of the Effectiveness Of Pomegranate Pills in Men With Prostate Cancer Before Prostatectomy
    Duke University Medical Center
    Durham, North Carolina 27710
    Prostate Cancer
    Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
    Duke Cancer Institute
    Durham, North Carolina 27710
    Cognitive/Functional Effects, Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Weight Changes
    BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma
    1200.36.0001 Boehringer Ingelheim Investigational Site
    Durham, North Carolina
    Glioma
    FTY720 in Patients With Primary Progressive Multiple Sclerosis
    Duke University
    Durham, North Carolina 27710
    Primary Progressive Multiple Sclerosis
    Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy
    Duke University Medical Center
    Durham, North Carolina 27710
    Breast Cancer
    Multimodality Phase II Study in Prostate Cancer
    Duke University
    Durham, North Carolina 27710
    Prostate Cancer
    An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients
    Duke University Medical Center
    Durham, North Carolina 27710
    Partial Mastectomy, Lumpectomy, Mastectomy
    Targeting Inattention in Childhood Cancer Survivors (TRICCS)
    Duke University Medical Center
    Durham, North Carolina 27710
    Acute Lymphoblastic Leukemia, Brain Tumor, Working Memory Deficits
    Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
    Duke University Medical Center
    Durham, North Carolina 27710
    Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Essential Thrombocythemia, Extramedullary Plasmacytoma, Intraocular Lymphoma, Isolated Plasmacytoma of Bone, Juvenile Myelomonocytic Leukemia, Long-term Effects Secondary to Cancer Therapy in Children, Mast Cell Leukemia, Meningeal Chronic Myelogenous Leukemia, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Primary Myelofibrosis, Primary Systemic Amyloidosis, Progressive Hairy Cell Leukemia, Initial Treatment, Prolymphocytic Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Stage 0 Chronic Lymphocytic Leukemia, Stage I Childhood Anaplastic Large Cell Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage I Childhood Large Cell Lymphoma, Stage I Childhood Lymphoblastic Lymphoma, Stage I Childhood Small Noncleaved Cell Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Multiple Myeloma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage II Childhood Anaplastic Large Cell Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage II Childhood Large Cell Lymphoma, Stage II Childhood Lymphoblastic Lymphoma, Stage II Childhood Small Noncleaved Cell Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Childhood Anaplastic Large Cell Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage III Childhood Lymphoblastic Lymphoma, Stage III Childhood Small Noncleaved Cell Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage IV Childhood Anaplastic Large Cell Lymphoma, Stage IV Childhood Hodgkin Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Childhood Lymphoblastic Lymphoma, Stage IV Childhood Small Noncleaved Cell Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocyte Leukemia, Unspecified Childhood Solid Tumor, Protocol Specific, Untreated Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
    Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors
    Duke University Medical Center
    Durham, North Carolina 27710
    Non-Small Cell Lung Cancer, Prostate Cancer, Pancreatic Cancer
    Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
    Duke Comprehensive Cancer Center
    Durham, North Carolina 27710
    Multiple Myeloma and Plasma Cell Neoplasm
    Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer
    Duke University Medical Center
    Durham, North Carolina 27710
    Prostatic Neoplasms
    Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD
    Duke University Medical Center
    Durham, North Carolina 27710
    Graft vs Host Disease, Graft-Versus-Host Disease
    A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer
    For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Durham, North Carolina
    Non-small Cell Lung Cancer
    Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
    Duke Comprehensive Cancer Center
    Durham, North Carolina 27710
    Breast Cancer, Menopausal Symptoms
    CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme
    Duke University Medical Center
    Durham, North Carolina 27710
    Glioblastoma Multiforme
    Efficacy and Safety Study of OncoVEXGM-CSF Compared to GM-CSF in Melanoma
    Duke University Medical Center
    Durham, North Carolina 27710
    Melanoma
    Neuropsychological and Behavioral Testing in Young Patients With Cancer
    Duke University Medical Center
    Durham, North Carolina 27710
    Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Neurotoxicity, Psychosocial Effects of Cancer and Its Treatment, Radiation Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
    Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
    Duke University Medical Center
    Durham, North Carolina 27710
    Male Breast Cancer, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
    Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC
    Duke University Medical Center

    Trial Locations
    Duke University Medical Center
    Durham VA Medical Center
    Non Small Cell Lung Cancer